Ali Moradi Kalan | Cancer Genetics | Editorial Board Member

Published on by Oncology

Dr. Ali Moradi Kalan | Cancer Genetics | Editorial Board Member 

Doctor | Medical School Tabriz | Iran

Ali Moradi Kalan is an oncology and public health–focused researcher affiliated with Tabriz University of Medical Sciences, with a scholarly profile reflecting strong contributions to cancer epidemiology, disease burden analysis, and population health research. With 966 total citations and an h-index of 5, his work demonstrates consistent academic influence, particularly in large-scale epidemiologic assessments and region-specific cancer reviews. His most highly cited contribution is a landmark 2021 Lancet study examining spatial, temporal, and demographic patterns of tobacco smoking and its attributable disease burden across 204 countries from 1990 to 2019, a publication that has significantly informed global tobacco control policies and cancer prevention strategies. In addition to global health modeling, he has led and co-authored systematic and narrative reviews on major cancers in Iran, including gastric and bladder cancer, providing critical insights into incidence trends, risk factors, and public health implications within the regional context. His research portfolio also spans interdisciplinary biomedical themes, such as the role of environmental toxins like arsenic in neuroinflammatory mechanisms and molecular studies exploring immunomodulatory and gene expression effects of nutritional and hormonal compounds. Through these works, he bridges epidemiology, clinical oncology, and mechanistic research, emphasizing prevention, early detection, and evidence-based policy. His publications appear in reputable international journals including The Lancet, Clinical and Experimental Gastroenterology, Research and Reports in Urology, Nutritional Neuroscience, and Journal of Molecular Neuroscience, underscoring the translational relevance and scientific rigor of his scholarship. Collectively, Ali Moradi Kalan’s research advances understanding of cancer burden and modifiable risk factors at both global and national levels, supporting improved public health planning, targeted interventions, and future oncology research, while positioning him as a contributor to data-driven cancer epidemiology and population-based health sciences.

Profile: Google Scholar

Featured Publications

Reitsma, M. B., Kendrick, P. J., Ababneh, E., Abbafati, C., Abbasi-Kangevari, M., Abdoli, A., … Moradi Kalan, A. (2021). Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: A systematic analysis from the Global Burden of Disease Study 2019. The Lancet, 397(10292), 2337–2360.

Kalan Farmanfarma, K., Mahdavifar, N., Hassanipour, S., & Salehiniya, H. (2020). Epidemiologic study of gastric cancer in Iran: A systematic review. Clinical and Experimental Gastroenterology, 13, 511–542.

Kalan Farmanfarma, K., Mahdavifar, N., & Salehiniya, H. (2020). Bladder cancer in Iran: An epidemiological review. Research and Reports in Urology, 12, 91–103.

Alizadeh-Ghodsi, M., Zavvari, A., Ebrahimi-Kalan, A., Shiri-Shahsavar, M. R., & colleagues. (2018). The hypothetical roles of arsenic in multiple sclerosis by induction of inflammation and aggregation of tau protein: A commentary. Nutritional Neuroscience, 21(2), 92–96.

Shiri-Shahsavar, M. R., Mirshafiee, A., Parastouei, K., Ebrahimi-Kalan, A., & colleagues. (2016). A novel combination of docosahexaenoic acid, all-trans retinoic acid, and 1,25-dihydroxyvitamin D3 reduces T-bet gene expression and serum interferon levels. Journal of Molecular Neuroscience, 60(4), 498–508.

Ali Moradi Kalan’s research advances global oncology and public health by generating high-impact evidence on cancer burden, tobacco exposure, and population-level risk factors that directly inform prevention strategies and health policy. Through rigorous epidemiologic analyses and region-specific cancer studies, his work strengthens data-driven decision-making, supports equitable cancer control, and contributes to sustainable improvements in global health outcomes.